Patient reported outcomes based on EQ-5D-5L questionnaires in head and neck cancer patients: a real-world study.
EQ-5D-5L
Head-and-neck cancer
Patient reported outcome
Radiotherapy
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
29 Nov 2022
29 Nov 2022
Historique:
received:
14
07
2022
accepted:
21
11
2022
entrez:
29
11
2022
pubmed:
30
11
2022
medline:
2
12
2022
Statut:
epublish
Résumé
Health economic comparisons of various therapies are often based on health-related quality of life (HRQOL) using EQ-5D questionnaires within the framework of clinical trials. This real-world study prospectively evaluates the patient reported outcomes (PROs)-based HRQOL of head-and-neck (H&N) cancer patients undergoing modern radiotherapy (RT) to reflect PRO trajectories. All H&N cancer patients treated in our clinic between July 2019 and December 2020 who completed the self-reported validated EQ-5D-5L questionnaire (health state index (HI) and Visual Analog Scale (VAS)) at baseline, end of radiotherapy, and at each respective follow up (FU) were included. Descriptive analysis of clinical and sociodemographic data, the frequency and level of each dimension was conducted. To assess the significance of therapy-induced HRQOL changes within and between the group, a distribution-based approach was used. Altogether, 366 participants completed a total of 565 questionnaires. For the whole cohort, HI at baseline was 0.804 (±0.208), 0.830 (±0.162) at RT completion, 0.812 (±0.205) at the first follow-up, and 0.769 (±0.224) at the second follow-up. The respective VAS values were 62.06 (±23,94), 66.73 (±82.20), 63.30 (±22.74), and 65.48 (±23.39). Females showed significantly lower HI values compared to males, but only at baseline (p = 0.034). Significantly lower HI values were also seen in patients with definitive RT as compared to adjuvant RT at baseline (p = 0.023), the second follow-up (p = 0.047), and the third follow-up (p = 0.010). As compared to outpatients, inpatients had significantly lower HI values at RT completion (p = 0.017), the second follow-up (p = 0.007), and the third follow-up (p = 0.031). Subgroup analyses by age (< 65 vs. ≥65) and smoking status (smokers vs. non-smokers) showed no difference at any time point. PROs demonstrated detectability of time- and intra-/inter-group therapy-induced HRQOL changes. A further detailed exploration of EQ-5D-5L responsiveness for H&N cancer patients is required.
Identifiants
pubmed: 36447175
doi: 10.1186/s12885-022-10346-4
pii: 10.1186/s12885-022-10346-4
pmc: PMC9710161
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1236Informations de copyright
© 2022. The Author(s).
Références
Value Health. 2009 Jul-Aug;12(5):750-8
pubmed: 19490564
Value Health. 2021 Apr;24(4):585-591
pubmed: 33840437
Med Care. 2007 Mar;45(3):259-63
pubmed: 17304084
Head Neck. 2012 Jul;34(7):974-80
pubmed: 21818820
Qual Life Res. 2013 Apr;22(3):475-83
pubmed: 22528240
Qual Life Res. 2020 Dec;29(12):3223-3232
pubmed: 32851600
Cancer. 2020 Mar 1;126(5):922-930
pubmed: 31743427
Eur J Health Econ. 2020 Nov;21(8):1245-1257
pubmed: 32514643
Head Neck. 2014 Jul;36(7):923-33
pubmed: 23595774
Strahlenther Onkol. 2011 Nov;187(11):744-9
pubmed: 22037655
Health Qual Life Outcomes. 2017 Jan 6;15(1):3
pubmed: 28069062
Health Technol Assess. 2014 Feb;18(9):1-224
pubmed: 24524660
GMS Health Technol Assess. 2011 Feb 02;7:Doc01
pubmed: 21468289
Oral Oncol. 2011 Aug;47(8):768-74
pubmed: 21683647
BMC Cancer. 2011 Apr 12;11:128
pubmed: 21486431
JMIR Res Protoc. 2020 Dec 9;9(12):e21693
pubmed: 33295291
Pharmacoeconomics. 2011 Jun;29(6):521-34
pubmed: 21247225
Value Health. 2021 Apr;24(4):568-574
pubmed: 33840435
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):687-699
pubmed: 27727066
Pharmacoeconomics. 2018 Jun;36(6):675-697
pubmed: 29470821
Eur J Health Econ. 2019 Aug;20(6):933-944
pubmed: 31030292
Eur J Cancer. 2020 Jan;124:178-185
pubmed: 31794928
JAMA. 2017 Jul 11;318(2):197-198
pubmed: 28586821
Qual Life Res. 2017 Aug;26(8):2079-2084
pubmed: 28332022
Pharmacoeconomics. 2018 Jun;36(6):645-661
pubmed: 29572719
Pharmacoeconomics. 2018 Jun;36(6):663-674
pubmed: 29460066
Value Health. 2021 Feb;24(2):250-267
pubmed: 33518032
Pharmacoeconomics. 2020 Jun;38(6):575-591
pubmed: 32180162
Appl Health Econ Health Policy. 2017 Apr;15(2):127-137
pubmed: 28194657
Eur J Cancer. 2012 Oct;48(15):2391-408
pubmed: 22579456
Health Qual Life Outcomes. 2020 Sep 29;18(1):317
pubmed: 32993637
Expert Rev Pharmacoecon Outcomes Res. 2020 Dec;20(6):673-682
pubmed: 32912005
Value Health. 2008 Mar-Apr;11(2):275-84
pubmed: 18380640
Value Health. 2020 May;23(5):649-655
pubmed: 32389231
Health Qual Life Outcomes. 2021 Mar 6;19(1):76
pubmed: 33676523
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
Health Qual Life Outcomes. 2006 Sep 27;4:70
pubmed: 17005038
Health Qual Life Outcomes. 2020 Apr 9;18(1):97
pubmed: 32272976